New oral drug enters human testing for devastating ALS
Disease control
Not yet recruiting
This early-stage study is testing a new oral drug called Kamlanoflast in 40 people with ALS (amyotrophic lateral sclerosis). The main goals are to check if the drug is safe and tolerable when taken for 24 weeks, and to see how it affects markers of inflammation and physical funct…
Phase: PHASE1, PHASE2 • Sponsor: Inflammasome Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC